What's Happening?
C-Ray Therapeutics has received a Radiopharmaceutical Production License under China's updated regulatory framework for outsourced pharmaceutical manufacturing. The license was granted following on-site inspections by the Sichuan Provincial Center for Drug
Evaluation and the National Defense Science and Industry Administration. This certification confirms C-Ray's compliance with stringent quality management systems and operational capabilities in radiopharmaceutical contract manufacturing. The company operates a modern cGMP-compliant facility in Chengdu, supporting over 30 radioisotopes and delivering more than 100 projects. The license strengthens C-Ray's foundation for future regulatory submissions and commercialization of partnered programs.
Why It's Important?
The authorization marks a significant milestone for C-Ray Therapeutics, enhancing its ability to manufacture radiopharmaceuticals under China's regulatory framework. This development positions C-Ray to expand its market presence and capitalize on the growing demand for radiopharmaceuticals in diagnostic and therapeutic applications. The license also underscores the importance of compliance and quality management in the pharmaceutical industry, particularly for contract development and manufacturing organizations. By securing this license, C-Ray can further its mission of providing high-quality, efficient radiopharmaceutical development services, potentially leading to increased collaborations and business opportunities.
